Clinical Trial Update: Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating donor lymphocyte infusion after allogeneic hematopoietic cell transplantation in patients with high-risk hematologic ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• Donor Lymphocyte Infusion

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hematologic Neoplasms | Phase 1, Phase 2 | Status: RECRUITING